Lipum AB (publ) (LIPUM.ST)
SEK 13.3
(-1.48%)
SEK 13.3
(-1.48%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -37.17 Million SEK | 2.79% |
| 2022 | -38.24 Million SEK | 27.02% |
| 2021 | -52.4 Million SEK | -147.93% |
| 2020 | -21.13 Million SEK | -126.89% |
| 2019 | -9.31 Million SEK | -385167.14% |
| 2018 | -2418.15 SEK | -5.83% |
| 2017 | -2284.97 SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -9.31 Million SEK | 1.46% |
| 2024 Q3 | -1.68 Million SEK | 91.06% |
| 2024 Q2 | -18.79 Million SEK | -101.83% |
| 2023 Q2 | -13.94 Million SEK | -93.68% |
| 2023 FY | -37.17 Million SEK | 2.79% |
| 2023 Q4 | -9.45 Million SEK | -43.09% |
| 2023 Q3 | -6.6 Million SEK | 52.65% |
| 2023 Q1 | -7.2 Million SEK | 45.13% |
| 2022 Q3 | -9.92 Million SEK | -6.24% |
| 2022 Q1 | -5.83 Million SEK | 80.02% |
| 2022 FY | -38.24 Million SEK | 27.02% |
| 2022 Q2 | -9.33 Million SEK | -60.15% |
| 2022 Q4 | -13.12 Million SEK | -32.32% |
| 2021 FY | -52.4 Million SEK | -147.93% |
| 2021 Q4 | -29.17 Million SEK | -418.96% |
| 2021 Q3 | -5.62 Million SEK | 50.46% |
| 2021 Q2 | -11.34 Million SEK | -85.78% |
| 2021 Q1 | -6.1 Million SEK | 37.44% |
| 2020 FY | -21.13 Million SEK | -126.89% |
| 2020 Q4 | -9.76 Million SEK | -1050.79% |
| 2020 Q3 | 1.02 Million SEK | 0.0% |
| 2019 FY | -9.31 Million SEK | -385167.14% |
| 2018 FY | -2418.15 SEK | -5.83% |
| 2017 FY | -2284.97 SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 85.044% |
| Ziccum AB (publ) | -21.41 Million SEK | -73.632% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -107.733% |
| BioArctic AB (publ) | 229.24 Million SEK | 116.217% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -8388.128% |
| Mendus AB (publ) | -101.61 Million SEK | 63.414% |
| Genovis AB (publ.) | 61.5 Million SEK | 160.452% |
| Intervacc AB (publ) | -102.85 Million SEK | 63.853% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -125.008% |
| Active Biotech AB (publ) | -45.8 Million SEK | 18.825% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 405.514% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | 34.57% |
| Aptahem AB (publ) | -11.11 Million SEK | -234.549% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 88.043% |
| Kancera AB (publ) | -64.88 Million SEK | 42.705% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 69.791% |
| Fluicell AB (publ) | -26.55 Million SEK | -40.009% |
| Saniona AB (publ) | -95.81 Million SEK | 61.196% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -206.547% |
| Biovica International AB (publ) | -124.82 Million SEK | 70.215% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 11.948% |
| AcouSort AB (publ) | -17.08 Million SEK | -117.555% |
| Xintela AB (publ) | -54.08 Million SEK | 31.258% |
| Abliva AB (publ) | -95.5 Million SEK | 61.074% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 88.627% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 790.271% |
| OncoZenge AB (publ) | -15.9 Million SEK | -133.794% |
| Amniotics AB (publ) | -30.87 Million SEK | -20.434% |
| 2cureX AB (publ) | -32.51 Million SEK | -14.331% |
| CombiGene AB (publ) | -35.66 Million SEK | -4.241% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | -189.819% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 92.025% |
| Camurus AB (publ) | 431.44 Million SEK | 108.617% |
| Corline Biomedical AB | -1.8 Million SEK | -1955.169% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 79.095% |
| Isofol Medical AB (publ) | -37.07 Million SEK | -0.289% |
| I-Tech AB | 20.2 Million SEK | 284.022% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 95.53% |
| Cyxone AB (publ) | -22.98 Million SEK | -61.721% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 59.324% |
| Biosergen AB | -27.03 Million SEK | -37.508% |
| Cantargia AB (publ) | -280.02 Million SEK | 86.723% |
| NextCell Pharma AB | -41.95 Million SEK | 11.396% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 79.307% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -126.723% |
| Nanologica AB (publ) | -75.15 Million SEK | 50.533% |
| SynAct Pharma AB | -215.81 Million SEK | 82.773% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | 15.608% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -56.625% |
| LIDDS AB (publ) | -40.2 Million SEK | 7.531% |
| BioInvent International AB (publ) | -330.3 Million SEK | 88.744% |
| Alzinova AB (publ) | -16.48 Million SEK | -125.595% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 85.076% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -274.4% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 67.193% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -76.274% |
| Simris Alg AB (publ) | -37.3 Million SEK | 0.34% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 75.517% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 90.422% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 65.982% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -218.359% |